Product image of Icatibant Piramal Critical Care (Icatibant) supplied by GNH India

Icatibant Piramal Critical Care

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Piramal Critical Care (Icatibant)

Icatibant, the active ingredient in Icatibant Piramal Critical Care, is a bradykinin B2 receptor antagonist presented as a sterile injectable solution for subcutaneous use. It treats acute attacks of hereditary angioedema in patients who experience recurrent swelling episodes.

GNH India supplies Icatibant Piramal Critical Care as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Piramal Critical Care Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to treat hereditary angioedema by blocking the bradykinin pathway that causes swelling.

  • Acute attacks of hereditary angioedema type I: provides rapid reduction of edema and associated pain.
  • Acute attacks of hereditary angioedema type II: provides rapid reduction of edema and associated pain.
  • Acute attacks of hereditary angioedema with normal C1‑inhibitor: offers symptom relief and helps restore airway patency.

How It Works

  • Icatibant selectively binds to the bradykinin B2 receptor on vascular endothelial cells, preventing bradykinin from activating the receptor. By blocking this interaction, the drug inhibits bradykinin‑induced vasodilation and increased vascular permeability, which are responsible for the swelling seen in hereditary angioedema. The antagonism is competitive and reversible, allowing normal receptor function to resume after the drug is cleared.

Side Effects

Icatibant may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling at injection site: localized erythema or edema.
  • Nausea: transient feeling of queasiness.
  • Headache: mild to moderate head pain.
  • Dizziness: brief sensation of lightheadedness.

Serious or Rare Side Effects

  • Anaphylactic reaction: severe allergic response requiring immediate medical attention.
  • Hypotension: sudden drop in blood pressure that may cause fainting.
  • Angioedema of the face or throat: swelling that can compromise airway.
  • Thrombocytopenia: low platelet count observed in rare cases.

Precautions & Warnings

When prescribing Icatibant, clinicians should observe several precautionary measures to ensure patient safety.

  • Assess hypersensitivity: verify no known allergy to icatibant or formulation components.
  • Monitor airway: observe for signs of airway obstruction during acute attacks.
  • Use with caution in cardiovascular disease: watch for hypotension or arrhythmias.
  • Consider renal/hepatic impairment: dose adjustment may be required in severe dysfunction.
  • Pregnancy and lactation: safety has not been established; avoid unless benefit outweighs risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medicines that influence the bradykinin system or cardiovascular function.

Major Interactions (Avoid)

  • ACE inhibitors: increase bradykinin levels and may reduce icatibant efficacy.
  • Neprilysin inhibitors: elevate bradykinin and could diminish therapeutic effect.
  • Estrogen‑containing oral contraceptives: may exacerbate angioedema risk.

Moderate Interactions (Monitor Closely)

  • Other bradykinin B2 receptor antagonists: additive pharmacodynamic effects.
  • Diuretics: monitor blood pressure for additive hypotensive effect.
  • NSAIDs: may increase risk of edema or hypersensitivity reactions.

Frequently Asked Questions

Icatibant is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients with type I, type II, or normal C1‑inhibitor HAE. It rapidly reduces swelling and associated symptoms during an attack.

Icatibant is a selective antagonist of the bradykinin B2 receptor. By binding to this receptor it blocks bradykinin‑induced vasodilation and increased vascular permeability, preventing the swelling that characterises hereditary angioedema.

The dose of Icatibant is set by the prescribing clinician based on the patient’s condition, weight and severity of the attack. It is administered as a subcutaneous injection, and the exact amount and timing are determined by the prescriber.

Safety of Icatibant during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request supply, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

The main alternative for HAE attacks is C1‑esterase inhibitor replacement therapy. Unlike plasma‑derived C1‑inhibitor products, Icatibant directly blocks the bradykinin B2 receptor, offering a rapid, subcutaneous option that does not involve protein replacement. Choice depends on patient preference, attack severity and clinical guidelines.

Icatibant should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Before use, allow the product to reach room temperature if required and inspect for particulate matter or discoloration.

Icatibant is administered as a single subcutaneous injection into the abdomen or thigh at the onset of an HAE attack. The injection can be performed by a trained healthcare professional or, after appropriate instruction, by the patient themselves.

The most serious adverse events include anaphylaxis, severe hypotension, and angioedema involving the face or throat that may compromise the airway. Immediate medical attention is required if any of these reactions occur.

Icatibant is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is also advised for individuals with severe cardiovascular disease, uncontrolled hypertension, or those taking medications listed under major interactions.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT